February 26, 2016 6:05pm

 

Good news all around however; traders will be booking profits in the next week

Ranking Friday’s pre-open indications – 4 hits and 1 misses.

 

Subscribe:  http://www.regmedinvestors.com/create-account   

 

 

Investors suffer from the paradox of information overload. If you have a smartphone in your pocket, you can access more information about the financial markets than the world's top hedge funds did 20 years ago. Yet, I bet your investment returns have not improved one iota as a result.

·         But, who is interpreting that information … get it here!

 

 

U.S. stocks closed mixed Friday, giving up most of their opening gains as oil reversed and inflation data increased expectations for a rate hike in the coming year.

The NASDAQ closed UP +8.27 or +0.18% to 4,590.47 and the DOW closed DOWN -57.32 or -0.34% to 16,639.97.

 

 

A day in the life of the stem, cell and gene therapy RegMed (SCGT & RM) sector – the advance/decline line scenario of our 43 covered companies.

  • Friday, the stem, cell and gene therapy RegMed sector opened positive with an A/DL of 29/12 and 2 flats;
  • The mid-day continued positive with an A/DL of 29/11 and 3 flats;
  • The closing bell rang positive with A/DL of 32/9 and 2 flats

 

 

Henry’omics:

The stem, cell and gene therapy RegMed (SCGT&RM) sector opened positive, stayed positive to the mid-day  and closed positive (of 43 covered companies).

  • Sitting in the 360% seat viewing … U.S. stocks wiped out earlier gains to finish generally lower on Friday, pulled down as crude-oil prices turned south. But all three main indexes closed higher for a second week in a row.

The Russell 2000 rose about 2.7% for the week, for its second-straight week of gains, and ending within 2o% of its 52-week intraday high, out of bear market territory.

  • SCGT&RM stocks were again traveling in a wider range versus the narrow ranges during the week.

 

Past five (5) days (of 43 covered companies):

·         Friday closed POSITIVE with 9 decliners, 32 advancers and 2 flat;

·         Thursday closed NEGATIVE with 23 decliners, 19 advancers and 1 flat;

·         Wednesday closed POSITIVE with 17 decliners, 23 advancers and 3 flats;

·         Tuesday closed NEGATIVE with 33 decliners, 8 advancers and 2 flats;

·         Monday closed POSITIVE with 8 decliners, 32 advancers and 3 flats

 

These are facts that investors have become accustomed to: the flop then the flip to the flop again!

  • In physics, escape velocity is the minimum speed needed for an object to break free from the gravitational attraction of a massive body. What is the “escape velocity” needed for stocks to break their down trend?
  • Unlike in physics, there is no fail-proof formula for stocks.

As compelling as historic patterns may be, tunnel vision is a luxury investors can't afford!

 

 

Friday’s handicapping the sector pre-open indications – 4 hits and 1 miss: 

  • Applied Genetic Technologies (AGTC) closed UP – hit;
  • BioLife Solutions (BLFS) closed DOWN – hit;
  • bluebird bio (BLUE) closed UP – hit;
  • Capricor (CAPR) closed DOWN – hit;
  • Kite Pharma (KITE) closed UP – miss;

 

 

Dosing the sector – what a day for the 43 Patients:

  • The market opened: POSITIVE with 12 decliners, 29 advancers and 2 flats;
  • The mid-day (12:30 pm: POSITIVE with 11 decliners, 29 advancers and 3 flats;
  • Closing bell: POSITIVE with 9 decliners, 32 advancers and 2 flats

 

 

Review my fear gauge or the CBOE Volatility Index (VIX) which is scary:

·         Friday traded near 19.8;

·         Thursday traded near 20;

·         Wednesday traded at 20.5;

·         Tuesday traded above 20;

·         Monday traded above 21;

·         Last, Friday traded near 20.5;

 

 

Riding the indexes and ETFs roller-coaster:

The iShares Biotechnology Stocks ETF (IBB) closed UP on Friday +2.17 or +0.84%

·         Thursday +0.54 or +0.21%

·         Wednesday +1.36 or +0.53%

·         Tuesday declined -6.20 or -2.35%

The NASDAQ Biotechnology index (NBI) closed UP on Friday +21.34 or +0.79%

·         Thursday +4.44 or +0.16%

·         Wednesday +14.38 or +0.53%

·         Tuesday declined -66.20 or -2.40%

The Russell 2000 (IWM) closed UP on Friday +8.65 or +0.63%

·         Thursday +0.93 or +0.92%

·         Wednesday +0.97 to 0.96%

·         Tuesday declined -0.93 or -0.92%

The SPDR SD&P Biotech ETF (XBI) closed UP on Friday +0.85 or +1.75%

·         Thursday -0.21 or -0.43%

·         Wednesday +0.52 or +1.08%

·         Tuesday declined  -2.42 or -4.78%

 

 

Who was UP – top 5:

  • Juno Therapeutics (JUNO) closed UP +$2.76 to $36.67;
  • Kite Pharma (KITE) +$2.26 to $47.37;
  • Intrexon (XON) +$2.21 to $33.76;
  • bluebird bio (BLUE) +$1.58 to $49.73;
  • Cellectis (CLLS) closed up +$1.39 to $22.89;

 

 

Who was leading the declines – to of the bottom 5?

  • uniQure (QURE) closed down -$0.53 to $14.67;
  • Mesoblast (MESO) -$0.34 to $6.07;
  • Athersys (ATHX) -$0.22 to $1.74;
  • Capricor (CAPR) -$0.23 to $2.27;
  • Northwest Bio (NWBO) closed down -$0.03 to $2.10

 

 

Who was FLAT?

  • ReNeuron (RENE.L) at $2.875;
  • VistaGen (VSTA) at $8.00                                    

 

 

Opinions expressed are those of the author and are subject to change, and not intended to be a forecast of future events, a guarantee of future results, nor investment advice.

Whether information or intelligence is good, bad or somewhere in between; I put into context what is relevant and useful for investors.  All investments are subject to risks. Investors should consider investment objectives.

Henry McCusker, the editor and publisher of RegMed Investors does not hold or have positions in securities referred to in this publication.